Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains unclear but may be due to immune destruction of circulating platelets in the peripheral blood. We present the case of acute-onset severe thrombocytopenia in a 76-year-old female undergoing percutaneous coronary intervention.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043518 | PMC |
| http://dx.doi.org/10.1080/20009666.2021.1871802 | DOI Listing |
Publication Analysis
Top Keywords
rare case
4
case eptifibatide-induced
4
eptifibatide-induced thrombocytopenia
4
thrombocytopenia eptifibatide
4
eptifibatide glycoprotein
4
glycoprotein iib/iiia
4
iib/iiia receptor
4
receptor antagonist
4
antagonist treatment
4
treatment acute
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!